Search Results for "CT P6 Celltrion"
By Kurt R. Karst – Earlier this week, Celltrion Healthcare Co., Ltd. and Celltrion, Inc. (collectively “Celltrion”) filed a Complaint for Declaratory Judgment in the U.S. District...
Celltrion, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct’s, ‘Celltrion, Inc. - Product Pipeline Review - 2014’, provides an overview of the Celltrion, Inc.’s pharmaceutic...
SEOUL, July 2 (Reuters) - Celltrion Inc said on Wednesday its top shareholder is no longer considering a sale of a stake in the biotechnology company.
Celltrion expects Korea’s National Health Insurance to cover Remsima and to start sales in the third quarter.
Following a Japanese approval last week Celltrion and partner Nippon Kayaku have claimed the US as the next target market for their Remicade (infliximab) biosimilar.
Celltrion Inc. (KOSDAQ:068270) filed suit in the U.S. District Court for the District of Massachusetts seeking a declaratory judgment that three patents from Johnson & Johnson (NYSE:JNJ) covering the...
South Korean biotechnology company Celltrion filed a lawsuit on 31 March 2014 in a federal court in Massachusetts seeking a declaratory judgement that Janssen Biotech’s (Janssen) remaining patents o...
South Korea’s Celltrion and Japanese partner Nippon Kayaku eye the U.S. for the next approval of their biosimilar of Johnson & Johnson’s Remicade.
Matching PubMed Articles